BurnsAdler Pharmaceuticals, Inc. Licenses NeoVisc® From Stellar Pharmaceuticals Inc.

Charlotte, North Carolina – (June 30, 2003) – BurnsAdler Pharmaceuticals, Inc. (“BurnsAdler”), an international pharmaceutical company, announced today that they have entered into a ten year licensing agreement with Stellar Pharmaceuticals, Inc. (“Stellar”) to market NeoVisc® (Sterile Sodium Hyaluronate Solution 1.0%) in South America, Central America and the Caribbean. Used for the treatment of osteoarthritis in the knee, shoulder or hip, NeoVisc® is indicated as a replacement/replenishment for synovial fluid. NeoVisc®, introduced in Canada in 1997, has quickly become one of the fastest growing viscosupplements. In the US market, the use of viscosupplements has grown to over $500 million dollars annually since their introduction in late 1997.

Back to news